论文部分内容阅读
耐药结核病人和HIV感染人群的迅速增加,使全球结核病疫情变得十分严峻。目前抗结核一线药物多为1946- 1966年通过传统随机筛选得到,主要针对生长期或分化期的结核分枝杆菌(MTB),作用于细胞壁生物合成、DNA复制、蛋白质合成等环节。近年新开发的利福霉素类药物(利福布汀、利福喷汀等)及新型喹诺酮类药物(左氧氟沙星、司帕沙星、莫昔沙星、加替沙星等),对部分耐药菌株有效,但没有实质性突破。迄至目前,尚缺乏理想的新型抗结核药物进入临床试验。人类在与结核病的斗争中,新药的研制和应用迫切需要,现就不同方面具有研发前景的抗结核新药的研究进展作一介绍。
The rapid increase of drug-resistant TB and HIV-infected people has made the global tuberculosis epidemic very serious. At present, most of the first-line anti-tuberculosis drugs are obtained through traditional random screening from 1946 to 1966. They are mainly targeted at Mycobacterium tuberculosis (MTB) in the growth phase or differentiation stage, and act on cell wall biosynthesis, DNA replication and protein synthesis. In recent years, the newly developed rifamycins (rifabutin, rifapentine, etc.) and new quinolones (levofloxacin, sparfloxacin, moxifloxacin, gatifloxacin, etc.), part of the resistance Drug strains effective, but no substantial breakthrough. Up to now, there is still a lack of ideal new anti-TB drugs to enter clinical trials. The urgent need for the development and application of new drugs in the fight against tuberculosis is presented in this article. The progress of the research on new anti-TB drugs with different aspects of research and development is introduced.